The translocator protein (TSPO) is prodromal to mitophagy loss in neurotoxicity

Mol Psychiatry. 2021 Jul;26(7):2721-2739. doi: 10.1038/s41380-021-01050-z. Epub 2021 Mar 4.

Abstract

Dysfunctional mitochondria characterise Parkinson's Disease (PD). Uncovering etiological molecules, which harm the homeostasis of mitochondria in response to pathological cues, is therefore pivotal to inform early diagnosis and therapy in the condition, especially in its idiopathic forms. This study proposes the 18 kDa Translocator Protein (TSPO) to be one of those. Both in vitro and in vivo data show that neurotoxins, which phenotypically mimic PD, increase TSPO to enhance cellular redox-stress, susceptibility to dopamine-induced cell death, and repression of ubiquitin-dependent mitophagy. TSPO amplifies the extracellular signal-regulated protein kinase 1 and 2 (ERK1/2) signalling, forming positive feedback, which represses the transcription factor EB (TFEB) and the controlled production of lysosomes. Finally, genetic variances in the transcriptome confirm that TSPO is required to alter the autophagy-lysosomal pathway during neurotoxicity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Autophagy
  • Humans
  • Lysosomes / metabolism
  • Mitochondria
  • Mitophagy*
  • Neurotoxicity Syndromes* / metabolism
  • Receptors, GABA* / genetics
  • Receptors, GABA* / metabolism

Substances

  • Receptors, GABA
  • TSPO protein, human